Treatment of Visceral Leishmaniasis in HIV Co-Infected Patients in East Africa and South-East Asia

Publication Date: June 7, 2022
Last Updated: July 5, 2022

WHO recommendations on treatment of visceral leishmaniasis in HIV co-infected patients

Visceral Leishmaniasis patients with HIV coinfection in East Africa

Liposomal amphotericin B + miltefosine: L-AMB (up to a total of 30 mg/kg, at 5 mg/kg on days 1, 3, 5, 7, 9 and 11) + miltefosine (100 mg/day for 28 days) over L-AMB: L-AMB (up to a total of 40 mg/kg, at 5 mg/kg on days 1-5, 10, 17 and 24). (C, VL)
620

WHO recommendation for secondary prophylaxis after recovery from a first episode of visceral leishmaniasis in HIV co-infected patients

Use secondary prophylaxis after recovery from a first episode of VL in HIV co-infected patients in East Africa. (C, VL)
620

Overview

Title

Treatment of Visceral Leishmaniasis in HIV Co-Infected Patients in East Africa and South-East Asia

Authoring Organization